COMPANY PROFILE / #3146
Baseimmune
London, United KingdomVenture Capital-Backed
OVERVIEW
Developer of a platform designed for pathogen analysis to create antigen and vaccine designs. The company's platform is based on a technology that can generate antigens using a level of informatics depth to tackle emerging and challenging pathogens, enabling healthcare providers to ensure the vaccines remain effective even if a pathogen mutates.
已融资16.78
最新估值40.97
员工数28
成立年份2019
公司概况
- Companies
- Baseimmune
- Description
- Developer of a platform designed for pathogen analysis to create antigen and vaccine designs. The company's platform is based on a technology that can generate antigens using a level of informatics depth to tackle emerging and challenging pathogens, enabling healthcare providers to ensure the vaccines remain effective even if a pathogen mutates.
- Website
- www.baseimmune.co.uk
- HQ Location
- London, United Kingdom
- Year Founded
- 2019
- Keywords
- antigens discovery, biologics, healthcare platform, infectious disease vaccines, pathogen detection, pathogens genomics, vaccines, vaccines testing
- Competitors
- SpyBiotech, Domainex, Kymab, Prokarium
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 16.78
- First Financing Date
- 01-Oct-2019
- First Financing Size
- 0.05
- First Financing Valuation
- —
- Last Financing Date
- 01-May-2024
- Last Financing Deal Type
- Accelerator/Incubator
- Last Financing Size
- —
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 40.97
- Last Known Valuation Date
- 20-Feb-2024
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 58.28
- Valuation Estimate Growth Rate
- 42.25%
- Active Investors
- Beast Ventures, BioIndustry Association, Cherry Ventures, Creator Fund, Hoxton Ventures, IQ Capital Partners, LifeArc, Maki.vc, Mike Watson, MSD Global Health Innovation Fund, P4 Precision, Rockmount capital, The Francis Crick Institute, Tiny Supercomputer Investment Company, Voyagers.io
- # Active Investors
- 15
- Acquirers
- —
团队与联系人
- Employees
- 28
- Employee Growth %
- 47.37%
- Employee History
- 2025: 28, 2024: 19, 2023: 14, 2022: 16, 2021: 8, 2020: 3, 2019: 3
- Primary Contact
- Kevin Walton
- Primary Contact Title
- Chief Executive Officer & Board Member
- Primary Contact Email
- kevin.walton@baseimmune.co.uk
- Primary Contact Phone
- +1 (212) 331-7847
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 1.13%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 98
- Size Multiple
- 4.92x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 80
- Majestic Referring Domains
- 128
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 8%
- Success Probability Over Time – 3 Year
- 26%
- Success Probability Over Time – 5 Year
- 36%
记录来源：public.companies · 原始序号 #3146 · 所有字段均按数据库原值展示。